Nice work, I am still sitting out, unlike all these people calling for announcements the reality of the situation is that the product still needs to translate to revenues.
The conference obviously got some attention, but what several people may not understand is that EmbryoCellect™ and DOPlify™ are for research use only and not able to be used as a clinical diagnostic. This translates to service agreements needing to be met with RHS to send samples for analysis, and imo this type of model in which clinics are not able to utilize the product in house is a barrier to creating consistent revenue in direct sales.
I could be wrong and still think this company has potential but will be waiting till it drops back to 5-8c before I come back in and hold until the next positive announcement. I sold also because there has been no 2016 annual report uploaded indicating the capital position of the company that somewhat concerned me considering it is April already.
It is also repeating the 2014 pattern that I mentioned previously when I sold out at 20c, sorry to anyone who got caught out at highs and I hope the company does shift towards positive upward momentum, but I can't see it in the mid-term
RHS Price at posting:
15.0¢ Sentiment: Hold Disclosure: Not Held
